Skip to content

PolitiKit

Lobbying by Boehringer Ingelheim (Canada) Ltd.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Client of a consultant lobbyist

Boehringer Ingelheim (Canada) Ltd.

Meetings this Parliament
4
With MPs
0
Since Nov 2021
4
Active registrations
0

Most recent reported meeting: Nov 17, 2025.

Registrations in effect

Boehringer Ingelheim (Canada) Ltd. has no active registration. Organizations must register once paid lobbying passes the legal threshold, and their registration ends when it stops.

Reported meetings

Spreadsheet

  • Reported by Emily-Jean Gallant · Consultant

    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    Arranging meetings for the client to brief government officials on the business of Boehringer Ingelheim Canada Ltd. Read more

    Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).

    Official report

  • Reported by Emily-Jean Gallant · Consultant

    • Manuela Tomic · Senior Advisor to the Minister, Innovation, Science and Economic Development Canada (ISED)
    Arranging meetings for the client to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Emily-Jean Gallant · Consultant

    • Mike Poitras · Director, Indigenous Relations Division, Public Health Agency of Canada (PHAC)
    • Elisha Hurlock · Manager, Indigenous Relations Division, Public Health Agency of Canada (PHAC)
    • Luke Carter · Executive Director, Indigenous, Federal, Provincial and Territorial Relations Directorate, Health Canada (HC)
    • Daniel MacDonald · Director General, Office of Pharmaceutical Management Strategies, Health Canada (HC)
    and 1 more
    • Russell Vallee · Manager, Office of Indigenous Affairs and Engagement, Health Canada (HC)
    Arranging meetings for the client to brief government officials on the business of Boehringer Ingelheim Canada Ltd. Read more

    Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).

    Official report

  • Reported by Emily-Jean Gallant · Consultant

    • Max Lee · Senior Communications Advisor to the Minister, Health Canada (HC)
    Arranging meetings for the client to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.